Black Diamond Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $127.0M
- Price
- $2.21
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.79%
- Volume
- 656.7K
About
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Quick stats
Shares outstanding57.5M
Computed float42.5M
Float / shares74.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001701541
AI Summary
AI-generated1/15
standardbullishearnings
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Black Diamond reported Q2 2026 financial results with a net loss of $9.9 million and cash, cash equivalents, and investments of $110.5 million, which is expected to fund operations into the second half of 2028.
The company provided a corporate update highlighting positive Phase 2 data for silevertinib, which showed an 86% CNS objective response rate and no de novo brain metastases in frontline non-classical EGFRm NSCLC patients.
Management selected a 150 mg once daily dose for pivotal development and anticipates providing an update on the Phase 2 trial and FDA feedback on a pivotal path in the fourth quarter of 2026.